The company released the Biopharma Compass 2.0 software, which automates workflows for high-resolution mass spectrometry.
On Jan. 24, 2017 Bruker announced the release of the Biopharma Compass 2.0 software that automates biopharmaceutical characterization (BPC) workflows for high-resolution mass spectrometry. The BPC 2.0 unifies data acquired from MALDI-TOF/TOF and ESI-UHR-QTOF mass spectrometry methods. BPC 2.0 offers a new 3D feature finder, supports 21CFR Part 11 compliance, full integration of UV and MS data, and wizards provide defining methods from acquisition to report generation. Data inspection is accelerated by automatically generated and color-coded analysis assessments.
Biopharma Compass 2.0 unifies the data acquisition, data analysis, and result reporting of biopharma workflows including:
Biopharma Compass 2.0 wizard-driven workflows allow for monoclonal antibody and antibody-drug conjugate (ADC) characterization, such as intact mass analysis, sequence errors, truncations, substitutions, and glycosylation.
Source: Bruker
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.